2 terminated, 1 completed. 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Completed 1 |
| Phase 3 | 2 | Terminated 2 |
Follow Umibecestat: new trials by email Literature Review of Umibecestat trials Research Report on Umibecestat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease CNP520 50mg, CNP520 15mg, Matching placebo - Alzheimers Disease | Phase 2 / Phase 3 | Terminated | Novartis Pharmaceuticals | 1145 | 2017-08-03 | 2021-08-05 |
| A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease CAD106 Immunotherapy, Placebo to CAD106, CNP520 - Alzheimers Disease | Phase 2 / Phase 3 | Terminated | Novartis Pharmaceuticals | 480 | 2015-11-30 | 2021-07-08 |
| Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age CNP520, Placebo - Alzheimer's Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 124 | 2015-08-10 | 2017-08-11 |
Alzheimer Disease (3) · Plaque, Amyloid (1)
Belgium (3) · Germany (3) · Netherlands (3) · United Kingdom (3) · United States (3) · Australia (2) · Canada (2) · Finland (2) · Spain (2) · Switzerland (2) · Argentina (1) · Chile (1) · China (1) · France (1) · Iceland (1)
1UF1AG046150-01 (1), 2015 (1), 2016 (1)